8 Best Biotech Stocks to Buy in 2022

For those of you who believe that, despite the recent market upset, tech still rules -- here are the latest recommendations from this week's U.S. News Invested for the best biotech stocks for 2022.  Hope everyone had a great weekend.  

SEPTEMBER 30, 2022 Invested Advice, rankings and stock market news for investors.

Happy Friday, investors! Stocks cave under recession anxiety, and Apple sheds 5% amid slow iPhone 14 sales and a BofA snub. Highlights of today's newsletter include our market insights plus these new articles: 8 Best Biotech Stocks to Buy in 2022 7 Best REIT ETFs to Buy 6 Best Health Care ETFs to Buy TODAY'S FEATURED STOCK STORY 8 Best Biotech Stocks to Buy in 2022 Biotechnology stocks are among the most high-risk, high-reward stocks in the market. The fates of these often volatile stocks are tied closely to study data and approval from the U.S. Food and Drug Administration or other global drug regulators. The biotech group has struggled as a whole in 2022, but the Morningstar analyst team says the innovation that has always supported the biotech industry is alive and well. Here are eight of Morningstar's top biotech stocks to buy: Gilead Sciences Inc. (ticker: GILD). Gilead Sciences develops treatments for infections, respiratory disorders, cardiovascular conditions and cancer. Analyst Karen Andersen says Gilead dominates the HIV treatment market and its emerging oncology division can be a significant future growth source. Gilead's tenofovir molecule has been the core of its $17 billion HIV division, and Andersen says the company's new tenofovir alafenamide combination pills are experiencing "rapid uptake." Gilead also pays a sizable 4.6% dividend. Morningstar has a "buy" rating and $77 fair value estimate for GILD stock, which closed at $63.93 on Sept. 28. Moderna Inc. (MRNA). Moderna is a leading biotechnology company in the field of mRNA therapeutics, and most investors likely know the company thanks to its leading COVID-19 vaccine. While COVID-19 vaccine sales growth has understandably slowed, Andersen says the stock remains undervalued given steady vaccine sales and the potential for Moderna's mRNA technology to support additional respiratory virus vaccines and vaccines for other infectious diseases. Morningstar has a "buy" rating and $232 fair value estimate for MRNA stock, which closed at $122.15 on Sept. 28. Click here to continue reading. 8 best biotech stocks to buy in 2022: Gilead Sciences Inc. (GILD) Moderna Inc. (MRNA) Biogen Inc. (BIIB) BioMarin Pharmaceuticals Inc. (BMRN) Incyte Corp. (INCY) Jazz Pharmaceuticals PLC (JAZZ) Exact Sciences Corp. (EXAS) Ionis Pharmaceuticals Inc. (IONS)